Lupin Biologics Profile
Key Indicators
- Authorised Capital ₹ 10.00 Cr
as on 10-12-2024
- Paid Up Capital ₹ 1.50 M
as on 10-12-2024
- Company Age 3 Year, 10 Months
- Last Filing with ROC 31 Mar 2024
- Revenue %
(FY 2022)
- Profit 94.51%
(FY 2022)
- Ebitda 94.51%
(FY 2022)
- Net Worth -37.49%
(FY 2022)
- Total Assets -81.40%
(FY 2022)
About Lupin Biologics
The Company is engaged in the Life Sciences Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2024. It's a company limited by shares with an authorized capital of Rs 10.00 Cr and a paid-up capital of Rs 1.50 M, as per Ministry of Corporate Affairs (MCA) records.
Vinita Gupta, Nilesh Gupta, and Swaminathan Ramesh serve as directors at the Company.
- CIN/LLPIN
U24299MH2021PLC354211
- Company No.
354211
- Company Classification
Public Limited Indian Non-Government Company
- Incorporation Date
28 Jan 2021
- Date of AGM
15 Jul 2024
- Date of Balance Sheet
31 Mar 2024
- Listing Status
Unlisted
- ROC Code
Roc Mumbai
Industry
Company Details
- Location
Mumbai, Maharashtra, India
- Telephone
- Email Address
- Website
- Social Media
Who are the key members and board of directors at Lupin Biologics?
Board Members(3)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Vinita Gupta  | Director | 28-Jan-2021 | Current |
| Swaminathan Ramesh | Director | 28-Jan-2021 | Current |
| Nilesh Gupta | Director | 28-Jan-2021 | Current |
Financial Performance and Corporate Structure Insights of Lupin Biologics.
Lupin Biologics Limited, for the financial year ended 2022, experienced no change in revenue, with a 0% increase. The company also saw a substantial improvement in profitability, with a 94.51% increase in profit. The company's net worth observed a substantial decline by a decrease of 37.49%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue | |||||||
| Revenue from Operations | |||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Lupin Biologics?
In 2021, Lupin Biologics had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
Lupin Digital Health LimitedActive 3 years 7 monthsNilesh Gupta and Swaminathan Ramesh are mutual person
Lupin Diagnostics LimitedActive 13 years 9 monthsNilesh Gupta and Swaminathan Ramesh are mutual person
Lupin Investments Private LimitedActive 40 years 3 monthsVinita Gupta and Nilesh Gupta are mutual person
Synchem Properties Private LimitedActive 9 years 1 monthVinita Gupta and Nilesh Gupta are mutual person
Charges (Loans)
There are no open charges registered against the company as per our records.
How Many Employees Work at Lupin Biologics?
Lupin Biologics has a workforce of 0 employees as of Apr 08, 2024. Unlock access to detailed historical data on individuals associated with the company, including employment records, contributions to the Employees' Provident Fund Organization (EPFO), and other related insights.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Lupin Biologics, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Lupin Biologics's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
